News

Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...
Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
At the American Society of Cell and Gene Therapy conference, there were questions and qualms on how Vinay Prasad may change ...
The new framework was well-received by biopharma analysts, who say it “largely formalizes” current COVID-19 vaccination ...
The U.S. Food and Drug Administration plans to require new clinical trials for approval of annual COVID-19 boosters for ...
A hot (if cautious) topic at the big gene therapy meeting: what Vinay Prasad's appointment might mean for approvals in rare ...
For a brief period in 2022, Dr. Vinay Prasad faked a concern about routine vaccines to infect unvaccinated children with ...
From claiming COVID vaccines were perfect and would end the pandemic to treating rare, temporary vaccine side-effects, even ...
Top officials in the Trump administration on Tuesday announced they will limit the approval of new COVID-19 vaccines to ...
The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...
Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen ...